<div id="readability-page-1"><p>In a report released today, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline, with a price target of <span id="expert-recommendation-target">£17.00</span>.</p><h3>Claim 50% Off TipRanks Premium and Invest with Confidence </h3><ul><li>Unlock  hedge-fund level data  and  powerful investing tools  designed to help you make smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  so your portfolio is always positioned for maximum potential</li></ul> <p>According to TipRanks, Sharma is a 3-star analyst with an average return of <span>3.3%</span> and a 57.78% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and arGEN X.</p> <p>In addition to Goldman Sachs, GlaxoSmithKline also received a Hold from Deutsche Bank ‘s Emmanuel Papadakis in a report issued yesterday. However, on December 10, HSBC maintained a Sell rating on GlaxoSmithKline (LSE: GSK).</p></div>

<p>Goldman Sachs analyst Rajan Sharma maintains a Hold rating for GlaxoSmithKline with a £17.00 price target. Sharma, a 3-star analyst, has a 3.3% average return and a 57.78% success rate. Deutsche Bank also issued a Hold rating, while HSBC maintained a Sell rating for GSK.</p>

Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)